[Thrombocyte aggregation and serum thromboxane B2 in patients with unstable angina pectoris treated with diltiazem or verapamil].
Patients with unstable angina pectoris have increased thrombocyte aggregation and disturbances in serum prostaglandin balance. As a pilot project, we conducted a single-blind investigation of 24 patients with unstable angina pectoris treated with dilthiazem (n = 12, 240-360 mg) or verapamil (n = 12, 240-360 mg) for ten days. At the commencement of the investigation, both patient groups had hyperaggregating thrombocytes and increased serum-thromboxan-B2 (TXB2) as compared to healthy individuals (p < 0.01). In the patient group treated with dilthiazem, the aggregation threshold rose (p < 0.01), and the serum TXB2 values fell to approximately normal (p < 0.05). In the patient group treated with verapamil, no significant changes were observed in the measurements registered. The difference between the two groups remained significant during the entire therapeutic period (p < 0.01). Thus, dilthiazem appears to counteract thrombocyte aggregation in patients with unstable angina pectoris.
Lyck
F
F
Medicinsk afdeling B, Rigshospitalet, København.
Holmvang
L
L
Grauholt
A M
AM
Grande
P
P
D000789:Angina, Unstable / Q000097:blood* / Q000188:drug therapy; D004110:Diltiazem / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood*; D014700:Verapamil / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D014700:Verapamil; D004110:Diltiazem
Trombocytaggregation og serum-tromboxan-B2 hos patienter med ustabil angina pectoris behandlet med diltiazem eller verapamil.